BioXcel Therapeutics is a biopharmaceutical company that uses artificial intelligence to develop transformative medicines for the treatment of neurological and oncological conditions. The company uses machine learning algorithms and big data to identify new therapeutic indices by leveraging existing validated product candidates. BioXcel's commercial product IGALMI aims to provide acute treatment for agitation associated with schizophrenia and bipolar disorders, and the company is also conducting clinical trials for various other disorders and conditions.